Beta-adrenergic blockade and the metabolic response to surgery

Area of Science:

• Anesthesiology and Perioperative Medicine
• Pharmacology and Therapeutics
• Metabolic and Endocrine Research

Background:

• Pelvic surgery can trigger significant metabolic and hemodynamic stress responses.
• Beta-adrenergic blockade is used to manage cardiovascular conditions but its metabolic impact during surgery is not fully understood.
• Understanding the metabolic effects of beta-blockers during surgery is crucial for patient safety.

Purpose of the Study:

• To investigate the metabolic effects of intravenous propranolol administration during pelvic surgery.
• To compare the metabolic and hemodynamic responses of patients receiving propranolol versus those who did not.
• To assess the safety and efficacy of beta-adrenergic blockade in the context of surgical stress.

Main Methods:

• A comparative study involving patients undergoing pelvic surgery.
• Administration of propranolol (0.15 mg/kg IV) to the treatment group.
• Monitoring of plasma insulin concentrations and glycemic response.
• Assessment of hemodynamic parameters throughout the surgical procedure.

Main Results:

• A significant difference was observed in plasma insulin concentrations, being lower in the propranolol group at 60 and 90 minutes post-surgery.
• The glycemic response to surgery was not impaired in patients treated with propranolol.
• No adverse hemodynamic effects were recorded in the propranolol-treated group.

Conclusions:

• Beta-adrenergic blockade with propranolol is unlikely to cause detrimental metabolic effects in healthy patients undergoing pelvic surgery.
• The observed reduction in insulin levels did not lead to impaired glycemic control.
• Propranolol appears to be metabolically safe in this surgical context, with no adverse hemodynamic consequences.